Adverse Effect Management and Monitoring Patients on BTK Inhibitors

SEQUOIA Arm C (Zanubrutinib for Del[17p] Treatment-Naive [TN]-CLL/SLL) and Arm D (Zanubrutinib + Venetoclax for TN-CLL/SLL)
Experts discuss the critical advancements in biomarker-driven frontline treatment for high-risk chronic lymphocytic leukemia (CLL), emphasizing the SEQUOIA trial’s evidence supporting targeted Bruton tyrosine kinase inhibitor monotherapy and combination therapies with venetoclax as effective, personalized, and well-tolerated options that improve progression-free survival and patient quality of life.

WATCH NOW



Featured Video

Adverse Effect Management and Monitoring Patients on BTK Inhibitors
Experts discuss how second-generation Bruton tyrosine kinase (BTK) inhibitors have enhanced chronic lymphocytic leukemia (CLL) management by offering improved tolerability and flexible dosing strategies that allow personalized, long-term therapy with manageable adverse effects and effective toxicity mitigation, thereby maintaining disease control while preserving patients’ quality of life.

WATCH NOW





 

購物車 會員登入